`
`BEFORE THE UNITED STATES
`JUDICIAL PANEL ON MULTIDISTRICT LITIGATION
`
`In re Ozempic® (Semaglutide) Patent
`Litigation
`
`)
`)
`)
`)
`)
`)
`)
`
`MDL No. ________________
`
`REASONS WHY ORAL ARGUMENT SHOULD BE HEARD
`
`Pursuant to Rule 11.1 (b) of the Rules of Procedure of the United States Judicial Panel on
`
`Multidistrict Litigation (the “Panel”), Novo Nordisk A/S and Novo Nordisk Inc. (collectively
`
`“Novo Nordisk”) respectfully request oral argument on their Motion for Transfer of the Action to
`
`the District of Delaware Pursuant to 28 U.S.C. §1407 for Coordinated and Consolidated Pretrial
`
`Proceedings.
`
`Oral argument will allow Novo Nordisk to further address the merits of this motion and
`
`any arguments made in opposition, thereby assisting the Panel in rendering a decision. Oral
`
`argument will allow the parties to respond to any inquires the Panel may have regarding the factual
`
`similarities of the pending Hatch-Waxman litigations, the burdens and challenges that litigating
`
`them separately will impose, the judicial efficiencies that will be realized through consolidation,
`
`and why Delaware is the appropriate transferee district. Finally, oral argument will ensure that the
`
`Panel has access to the views of all parties who wish to be heard in these six actions, including to
`
`update the Panel on any events that have occurred since briefing.
`
`For all of the foregoing reasons, Novo Nordisk respectfully requests that the Panel grant
`
`its request for oral argument.
`
`
`
`Case 1:22-cv-00023-JPB Document 22-10 Filed 05/06/22 Page 2 of 2 PageID #: 1819
`
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`
`/s/ Brian P. Egan
`_____________________________________
`Jack B. Blumenfeld (#1014)
`Brian P. Egan (#6227)
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@morrisnichols.com
`began@morrisnichols.com
`
`James F. Companion (W. Va. Bar No. 790)
`Sandra K. Law (W. Va. Bar No. 6071)
`SCHRADER COMPANION DUFF & LAW, PLLC
`401 Main Street Wheeling, WV 26003
`(304) 233-3390
`jfc@schraderlaw.com
`skl@schraderlaw.com
`
`Attorney for Novo Nordisk Inc. and
`Novo Nordisk A/S
`
`OF COUNSEL:
`
`Jeffrey J. Oelke
`Ryan P. Johnson
`Robert E. Counihan
`Laura T. Moran
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010-6035
`(212) 430-2600
`
`May 6, 2022
`
`2
`
`